Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD
1From the *Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; †Centre for Human Psychopharmacology, Swinburne University, Melbourne, Victoria, Australia; and ‡Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI.
Abstract:
Lapses of attention are characteristic for attention-deficit/hyperactivity disorder (ADHD) and as such may impair performance of daily activities. Data from an on-road driving study were reanalyzed to determine lapses in patients with ADHD after treatment with methylphenidate and placebo.A total of 18 adult ADHD patients performed a 100-km on-road driving test and were instructed to drive with a steady lateral position and constant speed. The SD of lateral position (SDLP), that is, the weaving of the car, lapses, and alertness, was assessed.Driving was significantly better (P = 0.006) with methylphenidate (SDLP, 18.8 cm) when compared with placebo (SDLP, 21.2 cm). Both the reduction in SDLP and the number of lapses (P = 0.003) confirm this significant improvement, which is further supported by subjective assessments of perceived driving performance. Although lapses were common in the placebo condition (11/18 patients), they were much less frequently observed (5/18 patients) after treatment with methylphenidate. Postdriving assessments suggest that lapses often go unnoticed by drivers.In conclusion, methylphenidate significantly improves driving of patients with ADHD by significantly reducing the number of lapses.
More Related Videos
09:43The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
Published on: August 10, 2014
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Narcolepsy
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
